Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Progen's puzzle piece

Progen Industries Ltd. has maintained that its PI-88 cancer compound has a dual mechanism: inhibition of angiogenesis and tumor metastasis. Teasing out the latter mechanism in humans can

Read the full 283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE